Last reviewed · How we verify
Direct-acting antiviral therapy
Direct-acting antiviral therapy targets viral replication by inhibiting viral enzymes.
Hospices Civils de Lyon is developing direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection, with ongoing trials in various populations including immunocompromised patients and transplant recipients. These DAAs aim to optimize antiviral treatment outcomes and expand therapeutic options.
At a glance
| Generic name | Direct-acting antiviral therapy |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Direct-acting antiviral |
| Target | Viral enzymes |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Direct-acting antivirals work by directly inhibiting viral enzymes, thereby preventing viral replication. This class of drugs has been shown to be effective in treating various viral infections.
Approved indications
- Hepatitis C
- Hepatitis B
Common side effects
- Fatigue
- Nausea
- Headache
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Direct-acting antiviral therapy CI brief — competitive landscape report
- Direct-acting antiviral therapy updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI